# US 11,298,377 B2 · Methods of improving wound healing

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,298,377 B2
- Document ID: US11298377B2
- Status: Granted
- Kind: B2
- Application number: 16/706,491
- Filed: 2019-12-06
- Published: 2020-04-30
- Granted: 2022-04-12
- Earliest claimed: 2018-10-26
- Assignees: Alkahest, Inc.
- Applicants: Alkahest, Inc.
- Inventors: Viktoria Kheifets; Benson Lu
- Web page: https://patentgrep.com/patent/US11298377B2

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0026: {Blood substitute; Oxygen transporting formulations; Plasma extender}
- A61K 38/38: Albumins
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure pertains to methods of improving wound healing. In certain embodiments, the methods comprise administering to a subject a Plasma Protein Fraction (PPF) in an amount that is effective to treat a wound.

## Claims

### Claim 1

A method of improving wound healing in a subject having a wound, the method comprising administering a Plasma Protein Fraction (PPF) to the subject in an amount effective to improve wound healing, wherein the PPF comprises between 83% and 95% albumin.

### Claim 2 (depends on 1)

The method of claim 1 wherein the wound is an acute wound.

### Claim 3 (depends on 1)

The method of claim 1 wherein the wound is a chronic wound.

### Claim 4 (depends on 3)

The method of claim 3 wherein the chronic wound is a diabetic wound.

### Claim 5 (depends on 1)

The method of claim 1 wherein the PPF is a commercially available PPF.

### Claim 6 (depends on 1)

The method of claim 1 wherein the administering is performed using a Pulse Dose dosing regimen.

### Claim 7 (depends on 1)

The method of claim 1 wherein the administering is performed topically.

### Claim 8 (depends on 1)

The method of claim 1 wherein PPF comprises at least 83% albumin and no more than 17% globulins and other plasma proteins.

### Claim 9 (depends on 8)

The method of claim 8 wherein PPF comprises no more than 1% gamma globulin.

### Claim 10

A method of improving wound healing in a subject having an acute wound, the method comprising topically administering to the acute wound a Plasma Protein Fraction (PPF) to the subject in an amount effective to improve wound healing of the acute wound, wherein the PPF comprises between 83% and 95% albumin.

### Claim 11 (depends on 10)

The method of claim 10 wherein the PPF is a commercially available PPF.

### Claim 12 (depends on 10)

The method of claim 10 wherein PPF comprises at least 83% albumin and no more than 17% globulins and other plasma proteins.

### Claim 13 (depends on 12)

The method of claim 12 wherein PPF comprises no more than 1% gamma globulin.

### Claim 14

A method of improving wound healing in a subject having a chronic wound, the method comprising topically administering a Plasma Protein Fraction (PPF) to the chronic wound of the subject in an amount effective to improve wound healing of the chronic wound, wherein the PPF comprises between 83% and 95% albumin.

### Claim 15 (depends on 14)

The method of claim 14 wherein the PPF is a commercially available PPF.

### Claim 16 (depends on 14)

The method of claim 14 wherein PPF comprises at least 83% albumin and no more than 17% globulins and other plasma proteins.

### Claim 17 (depends on 16)

The method of claim 16 wherein PPF comprises no more than 1% gamma globulin.

### Claim 18 (depends on 14)

The method of claim 14 wherein the chronic wound is a diabetic wound.